Image Source: Unsplash

The following companies are the "BIG 5" clinical-stage biopharmaceutical companies focused exclusively on developing psychedelic-based therapies for mental health conditions. The 5 have an average market capitalization of almost $600M and they have performed extremely well UP 34% YTD.

Below is a description of the focus of each, their market cap, performance YTD, in descending order, and analyst current consensus rating and price forecast for the next year:

1. atai Life Sciences N.V (ATAI): UP 199.2% YTD
   • Focus: It is generally considered a pure-play psychedelic stock, but unlike its peers, operates more like an incubator, investing in, and/or acquiring stakes in, promising psychedelic startups giving it broad exposure across the psychedelic landscape.
   • Market Cap: $868M
   • Analyst Consensus: The 3 analysts that cover Atai Life Sciences stock have a consensus rating of "Strong Buy" and an average price target which forecasts a 239% increase in the stock price over the next year. 
2. GH Research PLC (GHRS): UP 77.0% 
   • Focus: Its pipeline is focused on 5-MeO-DMT (also known as mebufotenin).targeting treatment-resistant depression, bipolar II disorder, and postpartum depression.
   • Market Cap: 786M
   • Analyst Consensus: The 8 analysts that cover GH Research stock have a consensus rating of "Strong Buy" and an average price target which forecasts a 144% increase in the stock price over the next year.
3. Cybin Inc. (CYBN):UP 59.7% YTD
   • Focus: Its entire pipeline revolves around modified psychedelic compounds such as a deuterated psilocybin analog in Phase 3 trials for major depressive disorder, a DMT-based compound in Phase 2 trials for generalized anxiety disorder and an Injectable DMT candidates for mood disorders, and a phenethylamine derivative targeting neuroinflammation (Phenethylamine is a natural monoamine alkaloid and trace amine found in the human brain and many foods and acts as a central nervous system stimulant, influencing mood, attention, and energy levels.)
   • Market Cap: $163M
   • Analyst Consensus: The 3 analysts that cover Cybin stock have a consensus rating of "Strong Buy" and an average price target which forecasts a 1,174% increase in the stock price over the next year
4. Mind Medicine (MindMed) Inc.(MNMD): UP 42.1% 
   • Focus: Its pipeline is focused on a proprietary formulation of LSD, currently in Phase 3 trials for generalized anxiety disorder and major depressive disorder, and an MDMA-like compound in Phase 1 trials, targeting core symptoms of autism spectrum disorder. 
   • Market Cap: $742M
   • Analyst Consensus: The 7 analysts that cover Mind Medicine (MindMed) stock have a consensus rating of "Strong Buy" and an average price target which forecasts a 159% increase in the stock price over the next year. 
5. COMPASS Pathways pic (CMPS): UP 9.8% YTD
   • Focus: Its entire pipeline is focused on a proprietary psilocybin formulation and is currently in Phase 3 clinical trials for treatment-resistant depression, with additional studies underway for PTSD and anorexia nervosa.
   • Market Cap: $409M
   • Analyst Consensus: The 6 analysts that cover COMPASS Pathways stock have a consensus rating of "Strong Buy" and an average price target which forecasts a 317% increase in the stock price over the next year.

Summary

The "BIG 5" are UP 33.9%, on average, YTD, with "Strong Buy" analyst ratings across the board and projected stock price increases averaging 335% in the next 12 months.

More By This Author:

Semiconductor Supplier, Applied Materials, Dropped Sharply Last Week - Here's Why
Intel And NXP Semiconductors Stocks Surged Last Week - Here's Why
No Wonder Microchip Was Down 8.5% Last Week: Here's Why